kneat.com, inc. (TSE:KSI - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$6.65 and last traded at C$6.65, with a volume of 40992 shares trading hands. The stock had previously closed at C$6.35.
Wall Street Analyst Weigh In
KSI has been the subject of several research reports. Cibc World Mkts upgraded shares of kneat.com to a "strong-buy" rating in a research report on Tuesday, October 29th. CIBC set a C$6.00 price target on shares of kneat.com and gave the company an "outperform" rating in a report on Tuesday, October 29th.
Check Out Our Latest Report on KSI
kneat.com Trading Down 2.8 %
The company has a 50-day moving average price of C$6.03 and a two-hundred day moving average price of C$5.19. The stock has a market cap of C$568.46 million, a P/E ratio of -41.31, a P/E/G ratio of 597.67 and a beta of 1.08. The company has a current ratio of 1.47, a quick ratio of 1.50 and a debt-to-equity ratio of 95.14.
kneat.com (TSE:KSI - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported C$0.01 EPS for the quarter, topping the consensus estimate of C($0.05) by C$0.06. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%. During the same quarter last year, the business earned ($0.05) earnings per share. On average, research analysts expect that kneat.com, inc. will post -0.12 EPS for the current fiscal year.
kneat.com Company Profile
(
Get Free Report)
kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.
Featured Stories
Before you consider kneat.com, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.
While kneat.com currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
